Strike down to zero
migraine pain
with Ubrelvy®

Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset3,4

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY 50 mg) vs 13% (placebo).3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1

UBRELVY has been prescribed over 2 million times by more than 80,000 HCPs, treating over 500,000 patients3

Ubrelvyhcp Hero Banner
ubrelvyhcp stamp.svg

THE POWER OF zero
migraine pain3
TAKEN ANYTIME, ANYWHERE1*

POWERFUL:
Zero pain, sustained1,3

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY® 50 mg) vs 13% (placebo).1,3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1,3,4

RAPID:
Quick pain relief1

Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset1,3,5

PRE-HEADACHE:
Clinical evidence3

Absence of headache pain of moderate to severe intensity within 24 hours after dosing in the pre-headache phase (primary endpoint)3

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Streamline the prescribing process

Get patients started

Once you've decided to prescribe UBRELVY, enable access for your patients with our UBRELVY Contact Center and learn how eligible commercially insured patients may pay as little as $0.

Help enable access
Prescribe the 16-count

16-count pack is available for your UBRELVY patients

Migraine attacks can be unpredictable.6 Prepare your patients with a 16-count package of UBRELVY 100 mg tablets.

View dosing
See the results of administering UBRELVY during the pre-headache phase.

Many patients experience
pre-headache symptoms7

See the results of administering UBRELVY during the pre-headache phase of a migraine attack.

Explore pre-headache data

*In clinical studies, patients took UBRELVY within 4 hours of a migraine attack.5

Eligibility: Available to patients with commercial insurance coverage for UBRELVY® (ubrogepant) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.ubrelvy.com/savings-terms or call 1-844-577-6239, for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.